Log In
BCIQ
Print this Print this
 

seribantumab (MM-121, SAR256212)

  Manage Alerts
Collapse Summary General Information
Company Merrimack Pharmaceuticals Inc.
DescriptionHuman mAb against erb-b2 receptor tyrosine kinase 3 (ERBB3; HER3; EGFR3)
Molecular Target Erb-b2 receptor tyrosine kinase 3 (ERBB3) (HER3) (EGFR3)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$530.0M

$60.0M

$470.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/05/2009

$530.0M

$60.0M

$470.0M

Get a free BioCentury trial today